Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Operating Leases (2019 - 2024)

Arcadia Biosciences' Operating Leases history spans 6 years, with the latest figure at $11000.0 for Q2 2024.

  • For Q2 2024, Operating Leases fell 97.93% year-over-year to $11000.0; the TTM value through Jun 2024 reached $11000.0, down 97.93%, while the annual FY2023 figure was $155000.0, 84.61% down from the prior year.
  • Operating Leases reached $11000.0 in Q2 2024 per RKDA's latest filing, down from $21000.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $5.7 million in Q2 2021 to a low of $11000.0 in Q2 2024.
  • Average Operating Leases over 5 years is $2.5 million, with a median of $1.6 million recorded in 2022.
  • Peak YoY movement for Operating Leases: surged 284.41% in 2020, then tumbled 97.93% in 2024.
  • A 5-year view of Operating Leases shows it stood at $5.4 million in 2020, then crashed by 58.8% to $2.2 million in 2021, then crashed by 54.64% to $1.0 million in 2022, then tumbled by 84.61% to $155000.0 in 2023, then plummeted by 92.9% to $11000.0 in 2024.
  • Per Business Quant, the three most recent readings for RKDA's Operating Leases are $11000.0 (Q2 2024), $21000.0 (Q1 2024), and $155000.0 (Q4 2023).